Bank Lviv (Lviv) has signed agreements with the European Investment Bank (EIB), the European Investment Fund (EIF), the Belgian Development Organization for Developing Countries (BIO) and the Bank of the Council of Europe (CoE) totaling EUR 103 million, which will allow it to expand financing to the private sector through credit lines, guarantees and support for micro-entrepreneurs.
“Within the framework of international partnerships, Lviv Bank has signed four strategic agreements with international financial institutions – for a total of more than EUR100 million to support Ukrainian private companies, SMEs and entrepreneurs!” Volodymyr Kuzio, deputy chairman of the bank’s board, said on Facebook on Tuesday.
He noted that Lviv Bank has attracted EUR 60 million from the EIB in the form of a multi-currency credit line, including local currency financing, to improve access to finance for the private sector.
Another EUR 35 million was provided by the EIF in the form of portfolio guarantees, which will reduce collateral requirements for Ukrainian private sector clients to 70% and at the same time strengthen the capital of Bank Lviv.
In addition, the bank will receive EUR 5 million from the Belgian development organization BIO, the first transaction in the institution’s history in Ukraine.
Another EUR 3 million is being provided by the Council of Europe Development Bank to support micro-entrepreneurs across the country.
According to the National Bank of Ukraine, as of April, Lviv Bank ranked 23rd in terms of total assets among 60 operating banks with UAH 14.8 billion, or 0.4% of the banking sector.
At URC-2025, SCM Group’s Intech investment company umgi has presented a project to build a grain terminal in Pivdennyi port with a planned annual transshipment capacity of 9 million tons and the ability to receive Post-Panamax vessels at its own berths. According to the press release, the estimated cost of the project is $200 million.
“We are pleased to join the recovery process. One of umgi’s initiatives was included in the Catalog of Investment Projects presented at the Ukraine Recovery Conference 2025 in Rome,” the company said in a statement.
It is specified that due to its strategic location and efficient infrastructure, such a terminal will play a key role in the export of Ukrainian agricultural products. This is a unique opportunity to invest in Ukraine’s strategic infrastructure, expand grain transportation capacity, and strengthen the country’s role in global trade.
Overall, the investment potential of key sectors of the Ukrainian economy over the next decade exceeds $300 billion. This figure includes rebuilding the destroyed sectors, transforming the economy and building a stable and environmentally friendly future. Realizing this potential will create a demand for equipment worth EUR33.8 billion annually in Ukraine.
A catalog with 250 current projects can be found here: https://kse.ua/…/07/Investment-catalog-Ukraine-2025.pdf
umgi is an investment company focused on the development of businesses in the raw materials and processing industries. It was founded in 2006 by SCM Group. Investment focus: mining; by-product and waste management; production of industrial goods and services. The total value of the portfolio companies is estimated at over $500 million.
Ukraine continues to strengthen its position in the European transit space. Thus, in the second quarter of 2025, the State Customs Service of Ukraine issued almost 34 thousand transit declarations under the common transit procedure (NCTS). This is 8 thousand more than in the previous quarter and 9 thousand more than in the second quarter of 2024.
This is the highest quarterly increase since Ukraine joined the Convention on a Common Transit Procedure.
More than 23 thousand movements initiated by Ukrainian customs have been successfully completed in the countries party to the Convention. In turn, 10.7 thousand transit movements initiated in other countries were completed in Ukraine, which is almost 50% more than in the previous quarter.
In total, since the start of the international application of the joint transit procedure on October 1, 2022, the State Customs Service has issued almost 196 thousand declarations, of which 149 thousand were issued as a customs office of departure and 47 thousand as a customs office of destination.
In addition, domestic companies are actively using Ukrainian general guarantees in T1 declarations to move transit goods in other countries party to the Convention. For example, in the second quarter of 2025, general guarantees were used in almost 106 thousand T1 declarations transported through the customs territory of the European Union (since January 1, 2025 – more than 183 thousand such declarations).
Regarding guarantees under the common transit procedure, in the second quarter of 2025, the State Customs Service registered 28 general guarantees in the NCTS guarantee management system. As of the beginning of July 2025, 94 general guarantees totaling more than EUR 320 million and 4,947 individual guarantees totaling EUR 218.45 million were in force.
Such dynamics confirms the growth of business confidence in the common transit procedure and demonstrates an increase in the number of foreign economic operators seeking to work in accordance with EU standards.
Ukraine plans to jointly manufacture lung and breast cancer drugs with Swiss pharmaceutical company Roche, Mykhailo Radutsky, chairman of the parliamentary committee on national health, medical care and medical insurance, said on his Facebook page, as part of the URC-2025 Ukraine Recovery Conference on Thursday.
“For several years, the President’s team has been negotiating with international pharmaceutical companies to localize production in Ukraine. The state enterprise “Medical Procurement of Ukraine” and Roche have signed an investment agreement to create capacities for the production of innovative drugs for lung and breast cancer in Ukraine,” he said.
Radutsky clarified that Roche will supply medicines in bulk, and their packaging, final packaging and labeling will be carried out directly in Ukraine, at the production facilities of the Ministry of Healthcare’s Medsnabzhenie branch.
He noted that in order to launch the project, it is necessary to obtain a GMP license for production and train staff.
Patients will be able to receive the first medicines under the project in 2027.
According to the State Enterprise (MoH), these are currently medicines for the two most common types of cancer – the drug for non-small cell lung cancer atezolizumab (Tecentrik) and pertuzumab + trastuzumab (Fesgo), which is used to treat breast cancer.
Since the beginning of the year, the ADONIS clinic chain has expanded the list of medical services to 80 areas, topping the Ukrainian Business Award TOP-10 private clinics rating by the number of medical areas.
According to the company’s pre-release, in 2024, the network had 78 medical areas. Among the areas in which ADONIS operates are gynecology, reproductive medicine, pediatrics, surgery, endocrinology, neurology, and others.
In addition, in 2025, ADONIS ranks second in the TOP 10 private clinics in terms of online brand awareness (branded searches) “This is an indicator of digital awareness – how many people consciously search for the clinic’s name on the Internet. In 2024, we were ranked fourth in this category, so we moved up two positions in a year, which indicates an increase in the popularity and trust in the ADONIS brand,” the clinic said.
ADONIS also took fourth place in the national ranking of private clinics, while in 2024 the chain also took fourth place, but within the city of Kyiv.
The clinic chain also received 8 out of 10 points for the quality of service, convenience of digital services, fast communication with patients, and overall level of service. In 2024, this figure was 7 points.
“The one-point increase is evidence that the implemented changes and systematic service improvement were noticeable to patients and had a positive impact on their experience,” the clinic emphasized.
In 2025, ADONIS received 86% of positive reviews on Google, while in 2024 this figure was approximately 83%.
In addition, ADONIS in 2025 received 3 out of 4 points for the level of representation in social networks.
“This indicator remained unchanged compared to 2024, which indicates stable activity in the digital environment. Thanks to regular content and systematic work with the online audience, the clinic continues to maintain the trust of patients on popular platforms,” the medical network emphasized.
ADONIS also received the highest score of 5 out of 5 points from the expert jury from all three independent jury members of the Ukrainian Business Award, with an average score of 4.9 in 2024.
“This result emphasizes the growth of brand confidence, consistency in development, and a high level of professionalism recognized by leading industry experts,” the network said.
ADONIS emphasized that the network “does not stop there, confirming its reputation as a stable and professional medical brand every year.”
“We are sincerely pleased with the results, which became possible thanks to the coordinated work of the entire team of the ADONIS medical group of companies – people who love their work and work with their hearts every day,” ADONIS emphasized.
On July 14, the price of Bitcoin exceeded $120,000 for the first time in history, reaching a peak of $122,571. After that, the price stabilized at around $121,950. The daily growth was about 2–3%, and since the beginning of the year — almost 29%. Analysts attribute the dynamics to a massive influx of capital into Bitcoin-based exchange-traded funds (BTC-ETFs) — over $1 billion daily — and favorable expectations regarding regulation. This refers to the active debate surrounding the Genius Act bill and discussions during Crypto Week.
Institutional players, including giants such as BlackRock and Bitwise, are showing unprecedented activity: from January to July, net inflows into cryptocurrency products exceeded $14.4 billion. Bitcoin is increasingly being treated as a digital analogue of gold — a “store of strength” in times of financial volatility. Technical analysis indicates potential growth to $125,000–131,000 in the coming weeks. If the trend remains stable, the price could reach $200,000–250,000 by the end of the year.
Ethereum is not far behind. ETH updated its five-month high, rising to $3,060. Open interest in Ethereum futures reached $14.25 billion, and ETF inflows exceeded $1 billion. AI-based predictive models see ETH in the $3,000–3,200 range throughout July.
The altcoin market is also showing positive dynamics. XRP rose above $2.80, an increase of 6–7% over the week. The technical picture shows a breakout from the falling wedge formation, opening the way to $3 and possibly $4.35 as early as July. Solana is trading at $160–167, with potential to reach $186–200, while Cardano (ADA) is near $0.725 and showing an upward trend to $0.77. Investors are showing growing interest in assets such as CELO and DOGE, as well as new staking ETFs, particularly those based on Solana.
The total capitalization of the crypto market is approaching $3.8 trillion. Despite geopolitical instability, the market is showing a clear bullish trend. Central bank digital initiatives, including digital currency pilots (CBDCs) in Australia, are creating a favorable backdrop for further growth in crypto assets. Against this backdrop, Bitcoin is increasingly consolidating its status as a reserve asset, prompting large institutions and companies to withdraw significant amounts from traditional assets in favor of digital ones.
